Augustine Therapeutics

Novel HDAC6 Inhibitors for Chronic Disease

Leuven, Belgium · Founded 2025 · $90.6M raised

Headquarters
Leuven
Founded
2025
Business Model
B2B
Total Funding
$90.6M
Last Round
$90.6M Series AMar 2025
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Founded in 2019 as a spin-off from VIB and KU Leuven, Augustine Therapeutics is pioneering a new era in HDAC6-targeted drug development. Its work builds on research into HDAC6's critical role in peripheral neuropathies like Charcot-Marie-Tooth disease and Chemotherapy-Induced Peripheral Neuropathy, as well as neurodegenerative disorders such as ALS. Charcot-Marie-Tooth disease progressively weakens muscles, causes severe pain, and lacks any approved treatments. The company's mission is to bring transformative therapies to patients suffering from complex neurological diseases.

Summary

Augustine Therapeutics is a Biotech company based in Leuven, Belgium, founded in 2025. It has raised $90.6M in total across 1 round, most recently a $90.6M Series A round in Mar 2025. Investors include Novo Holdings A/S, Jeito Capital and Asabys Partners.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AMar 2025
$90.6M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Augustine Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/augustine-therapeutics"><img src="https://indexed.vc/api/badge/company/augustine-therapeutics" alt="Augustine Therapeutics on Indexed.vc" width="260" height="76" /></a>